- Home
- JANX vs AIR Comparison
JANX vs AIR Comparison
Compare JANX & AIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- AIR
- Stock Information
- Founded
- JANX 2017
- AIR 1951
- Country
- JANX United States
- AIR United States
- Employees
- JANX N/A
- AIR N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- AIR Aerospace
- Sector
- JANX Health Care
- AIR Industrials
- Exchange
- JANX Nasdaq
- AIR Nasdaq
- Market Cap
- JANX 1.6B
- AIR 2.0B
- IPO Year
- JANX 2021
- AIR 1988
- Fundamental
- Price
- JANX $26.37
- AIR $59.62
- Analyst Decision
- JANX Strong Buy
- AIR Strong Buy
- Analyst Count
- JANX 7
- AIR 6
- Target Price
- JANX $94.29
- AIR $80.67
- AVG Volume (30 Days)
- JANX 974.6K
- AIR 247.0K
- Earning Date
- JANX 05-20-2025
- AIR 03-27-2025
- Dividend Yield
- JANX N/A
- AIR N/A
- EPS Growth
- JANX N/A
- AIR N/A
- EPS
- JANX N/A
- AIR N/A
- Revenue
- JANX $10,588,000.00
- AIR $2,682,500,000.00
- Revenue This Year
- JANX N/A
- AIR $18.46
- Revenue Next Year
- JANX $250.58
- AIR $5.10
- P/E Ratio
- JANX N/A
- AIR N/A
- Revenue Growth
- JANX 30.99
- AIR 21.07
- 52 Week Low
- JANX $22.52
- AIR $46.51
- 52 Week High
- JANX $71.71
- AIR $76.34
- Technical
- Relative Strength Index (RSI)
- JANX 39.10
- AIR 61.75
- Support Level
- JANX $31.34
- AIR $52.49
- Resistance Level
- JANX $33.97
- AIR $57.32
- Average True Range (ATR)
- JANX 1.94
- AIR 1.59
- MACD
- JANX -0.52
- AIR 1.22
- Stochastic Oscillator
- JANX 22.76
- AIR 94.25
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About AIR AAR Corp.
AAR Corp is engaged in providing products and services to aviation, government, and defense market. It operates in three segments namely Parts Supply, Repair & Engineering, and Integrated Solutions. The parts supply segment majorly consists of sales and leasing of USM and aftermarket distribution of new, OEM-supplied replacement parts. Repair & Engineering segment provides airframe maintenance, component repair, and landing gear overhaul services. Integrated Solutions segment majorly consists of its fleet management and operations of customer-owned aircraft, customized performance-based supply chain logistics programs in support of the U.S. Department of Defense and foreign governments, flight hour component inventory and repair programs for commercial airlines.